Stifel raised the firm’s price target on Ascendis Pharma (ASND) to $207 from $200 and keeps a Buy rating on the shares. The firm has updated its model to reflect the recent equity financing, as well as near-term milestone payments from the Novo cardiometabolic collaboration agreement, and Q3 results.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND: